The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2024-07-12 DOI:10.2147/jaa.s451733

Pongsakorn Tantilipikorn, Virat Kirtsreesakul, Chaweewan Bunnag, Mukda Vangveeravong, Sanguansak Thanaviratananich, Supinda Chusakul

{"title":"The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review","authors":"Pongsakorn Tantilipikorn, Virat Kirtsreesakul, Chaweewan Bunnag, Mukda Vangveeravong, Sanguansak Thanaviratananich, Supinda Chusakul","doi":"10.2147/jaa.s451733","DOIUrl":null,"url":null,"abstract":"Abstract: The incidence of allergic rhinitis (AR) in Asia and the world is steadily rising. Patients experience incomplete symptom relief despite existing treatment options, which warrants the need for new therapeutic regimes. Azelastine hydrochloride/fluticasone propionate (MP-AzeFlu), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate has been indicated in the treatment of AR. The current review discusses the effects of MP-AzeFlu versus conventional therapies in achieving superior clinical improvement with a very rapid onset of action (5 minutes). The superiority of MP-AzeFlu in offering complete symptom control with sustained relief in patients with AR compared to the existing therapeutic options is also discussed. MP-AzeFlu has been shown to improve the quality of life for patients with AR, thereby enhancing patient adherence to therapy and establishing its preference for the treatment of AR. Currently, the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend the use of a combination of intranasal corticosteroids and intranasal antihistamines as first-line treatment in patients with persistent AR with visual analog scores ≥ 5 or when prior treatment with single agents has been ineffective. Widely published data on the efficacy and safety of its prolonged use in adults and children have validated that effective treatment of AR can be achieved with MP-AzeFlu. Keywords: fixed-dose combination, intranasal, MP-AzeFlu, corticosteroids, antihistamines ","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"154 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/jaa.s451733","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: The incidence of allergic rhinitis (AR) in Asia and the world is steadily rising. Patients experience incomplete symptom relief despite existing treatment options, which warrants the need for new therapeutic regimes. Azelastine hydrochloride/fluticasone propionate (MP-AzeFlu), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate has been indicated in the treatment of AR. The current review discusses the effects of MP-AzeFlu versus conventional therapies in achieving superior clinical improvement with a very rapid onset of action (5 minutes). The superiority of MP-AzeFlu in offering complete symptom control with sustained relief in patients with AR compared to the existing therapeutic options is also discussed. MP-AzeFlu has been shown to improve the quality of life for patients with AR, thereby enhancing patient adherence to therapy and establishing its preference for the treatment of AR. Currently, the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend the use of a combination of intranasal corticosteroids and intranasal antihistamines as first-line treatment in patients with persistent AR with visual analog scores ≥ 5 or when prior treatment with single agents has been ineffective. Widely published data on the efficacy and safety of its prolonged use in adults and children have validated that effective treatment of AR can be achieved with MP-AzeFlu.

Keywords: fixed-dose combination, intranasal, MP-AzeFlu, corticosteroids, antihistamines

查看原文本刊更多论文

盐酸阿折拉斯汀/丙酸氟替卡松在亚洲过敏性鼻炎治疗中的应用：综述

摘要：过敏性鼻炎（AR）在亚洲和全球的发病率正在稳步上升。尽管有现有的治疗方案，但患者的症状缓解不彻底，因此需要新的治疗方案。盐酸氮卓斯汀/丙酸氟替卡松（MP-AzeFlu）是盐酸氮卓斯汀和丙酸氟替卡松的新型鼻内制剂，已被用于治疗鼻炎。本综述讨论了 MP-AzeFlu 与传统疗法相比，在快速起效（5 分钟）改善临床症状方面的效果。此外，还讨论了 MP-AzeFlu 与现有治疗方案相比，在完全控制 AR 患者症状并持续缓解症状方面的优越性。事实证明，MP-AzeFlu 可改善 AR 患者的生活质量，从而提高患者对治疗的依从性，并确立其在 AR 治疗中的优先地位。目前，过敏性鼻炎及其对哮喘的影响（ARIA）指南建议将鼻内皮质类固醇激素和鼻内抗组胺药物联合使用，作为视觉模拟评分≥5 分或之前单药治疗无效的持续性 AR 患者的一线治疗方法。在成人和儿童中长期使用MP-AzeFlu的疗效和安全性的广泛数据已经证实，MP-AzeFlu可以有效治疗AR。关键词：固定剂量复方制剂；鼻内用药；MP-AzeFlu；皮质类固醇；抗组胺药

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.